Devita, Hellman, and Rosenberg's Cancer

LWBK1006-31 LWW-Govindan-Review December 12, 2011 19:43

CHAPTER 31 ACUTE LEUKEMIAS

JOHN WELCH•AMANDA F. CASHEN

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 31.1. The favorable cytogenetic rearrangement in acute myeloid leukemia

(AML) resulting from the t(8;21) juxtaposes which genes?

A. AML1-ETO

B. RUNX1-RUNX1T1

C. A core-binding factor and a zinc finger protein

D. All of the above

Question 31.2. You are caring for a 25-year-old woman with AML-M2 and normal cyto-

genetics. She receives 7+3 induction therapy, and her day-14 bone mar-

row biopsy is ablated. She returns to clinic and her day-45 bone marrow

shows normal hematopoeisis, however, she relapses after 18 months.

Which of the following likely contributed to her relapse?

A. DNMT3A mutation

B. CEBPA mutation

C. NPM mutation without FLT3-ITD

D. Her age

Question 31.3. Your well-read 30-year-old patient with AML asks you how you will

follow her disease once she is in remission. She asks which is the most

sensitive test for minimal residual disease? In which order are these assays

most sensitive (least to most sensitive)?

A. Cytopathology <fluorescence in situ hybridization (FISH)

<polymerase chain reaction (PCR)

B. FISH<cytogenetics<PCR

C. PCR<cytopathology<FISH

D. Cytogenetics<PCR<flow cytometry

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 130 (Molecular Biology of

Acute Leukemias) and 131 (Management of Acute Leukemias).

437